时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
By mapping the current clinical landscape, we aim to highlight key challenges and emerging opportunities in pulmonary regenerative medicine for COPD.MethodsClinical trials investigating stem cell-based therapies for COPD were identified using the Trialtrove database (https://pharma.id.informa.com/) through October 1, 2025, and cross-validated using ClinicalTrials.gov (https://clinicaltrial.gov/).
方法
By mapping the current clinical landscape, we aim to highlight key challenges and emerging opportunities in pulmonary regenerative medicine for COPD.MethodsClinical trials investigating stem cell-based therapies for COPD were identified using the Trialtrove database (https://pharma.id.informa.com/) through October 1, 2025, and cross-validated using ClinicalTrials.gov (https://clinicaltrial.gov/).；COPD, chronic obstructive pulmonary disease.Charts labelled A to F showing annual trial distribution, trial phase and status, outcome disclosure, therapeutic cell types, sponsor types, and geographic distribution of COPD stem cell trials.Trial status and outcome disclosureAmong the 43 identified trials, 58.1% had been completed, 18.6% were open or planned, and 18.6% were terminated prematurely, primarily due to low enrollment (n = 3), business decisions (n = 1), COVID-19 disruptions (n = 2), and unknown reasons (n = 2) (Figure 2B and C).；Brazil contributed the largest number of publicly available outcome reports (n = 4), followed by Australia and the United States (n = 2 each), whereas China contributed only 1 publicly available outcome report (Figure 2F).Sponsor-stratified trial characteristicsWe further performed a sponsor-stratified analysis comparing industry-sponsored and academically sponsored trials (Table 2).
核心结论
Overall, the publicly available studies reported no major short-term safety concerns for the specific cell products evaluated, whereas efficacy remained heterogeneous.；Our findings reveal a field that has sustained academic momentum over nearly 2 decades yet remains at an early translational stage, with MSC-based and mixed-cell approaches still predominating and bronchial basal progenitor cell-based or cell-free strategies emerging as exploratory directions.Phase distribution and translational barriersThe concentration of trials in Phase I-II reflects a field still primarily engaged in establishing safety and feasibility rather than demonstrating efficacy at scale.；These findings provide preliminary support for the short-term tolerability of the evaluated interventions but should not be generalized to stem cell therapies as a whole.
局限
However, this pattern was not reflected in the distribution of publicly available outcome reports.；However, the outcome disclosure rate of only 44% among completed trials represents a critical deficiency that undermines the field’s credibility and impedes evidence synthesis.；However, the current evidence remains limited, and more high-quality clinical data are needed to establish the efficacy of stem cell-based therapies for COPD.Sponsorship patterns and reporting transparencySponsor-stratified analysis suggests that academic institutions have been the primary drivers of COPD stem cell therapy development.
对本项目的价值
中高价值：属「干细胞 / 部分重编程与再生」方向；干细胞 / 再生 / 重编程栏目可用作本项目文献库与综述素材。 ｜ 价值分 3.3/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 26,669 字符，题名指纹 1.0，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：干细胞治疗慢性阻塞性肺疾病：全球临床试验版图
- 英文标题：Stem cell therapies for chronic obstructive pulmonary disease: mapping the global clinical trial landscape.
- 期刊与标识：Stem cells translational medicine · PMID 42970715 · DOI 10.1093/stcltm/szag087 · PMC PMC13726808